Riabni clinical trials
Riabni is named as an intervention in 20 current clinical trials in our Israel, Canada, Australia, USA, Poland, Mexico, Italy, China, Japan, South Korea, Taiwan, UK, France, Spain, Denmark, Turkey, Brazil, Belgium, Singapore, Ireland, Germany, Switzerland, Czechia, Portugal, Egypt, Sweden, Norway, Austria and Netherlands registers. 7 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is National Cancer Institute (NCI) (8). The most-studied condition is Chronic Lymphocytic Leukemia.
Patient leaflets for Riabni
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Riabni
20 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Riabni
34 conditionsAll 34 conditions
| Condition (as registered) | Trials |
|---|---|
| Chronic Lymphocytic Leukemia | 4 |
| Small Lymphocytic Lymphoma | 4 |
| Diffuse Large B-Cell Lymphoma | 3 |
| Lymphoma | 3 |
| Acute Lymphoblastic Leukemia | 2 |
| Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | 2 |
| Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | 2 |
| Mantle Cell Lymphoma | 2 |
| Lymphoma, Large B-Cell, Diffuse | 1 |
| DLBCL | 1 |
| Follicular Lymphoma | 1 |
| B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | 1 |
| Nodular Lymphocyte Predominant B-Cell Lymphoma | 1 |
| Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma | 1 |
| Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma | 1 |
| Acute Myeloid Leukemia | 1 |
| Mixed Phenotype Acute Leukemia | 1 |
| Myelodysplastic Syndrome | 1 |
| Stage I Chronic Lymphocytic Leukemia | 1 |
| Stage II Chronic Lymphocytic Leukemia | 1 |
| Stage III Chronic Lymphocytic Leukemia | 1 |
| Stage IV Chronic Lymphocytic Leukemia | 1 |
| Primary Mediastinal Large B-Cell Lymphoma | 1 |
| Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 1 |
| Double-Expressor Lymphoma | 1 |
| EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 1 |
| Anemia | 1 |
| Ann Arbor Stage II Diffuse Large B-Cell Lymphoma | 1 |
| Marginal Zone Lymphoma | 1 |
| MZL | 1 |
| Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma | 1 |
| Diffuse Large B-Cell Lymphoma Activated B-Cell Type | 1 |
| Diffuse Large B-cell Lymphoma (DLBCL) | 1 |
| Cardiotoxicity | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 8 |
| Merck Sharp & Dohme LLC | 5 |
| Loxo Oncology, Inc | 2 |
| Children's Oncology Group | 1 |
| Gottfried von Keudell, MD PhD | 1 |
| ECOG-ACRIN Cancer Research Group | 1 |
| Beth Israel Deaconess Medical Center | 1 |
| Christine Ryan | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Riabni trials
How many clinical trials are testing Riabni?
20 current trials in our Israel, Canada, Australia, USA, Poland, Mexico, Italy, China, Japan, South Korea, Taiwan, UK, France, Spain, Denmark, Turkey, Brazil, Belgium, Singapore, Ireland, Germany, Switzerland, Czechia, Portugal, Egypt, Sweden, Norway, Austria and Netherlands registers name Riabni as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Riabni trials recruiting patients?
Yes. 7 of the 20 trials are recruiting: 6 with sites in Israel, 3 with sites in Canada, 3 with sites in Australia, 4 with sites in USA, 4 with sites in Poland, 2 with sites in Mexico, 4 with sites in Italy, 3 with sites in China, 3 with sites in Japan, 3 with sites in South Korea, 2 with sites in Taiwan, 2 with sites in UK, 2 with sites in France, 2 with sites in Spain, 2 with sites in Denmark, 3 with sites in Turkey, 2 with sites in Brazil, 2 with sites in Belgium, 1 with sites in Singapore, 1 with sites in Ireland, 1 with sites in Germany, 1 with sites in Switzerland, 1 with sites in Portugal, 1 with sites in Egypt and 1 with sites in Netherlands. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Riabni clinical trials?
National Cancer Institute (NCI) (8), Merck Sharp & Dohme LLC (5), Loxo Oncology, Inc (2) and Children's Oncology Group (1), among 8 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Are there Riabni clinical trials in Ireland?
Yes. 2 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Riabni works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Riabni works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Riabni (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.